Narcolepsy can lead to excessive daytime sleepiness, as well as cataplexy, a sudden loss of muscle tone. Other symptoms can include sleep paralysis and hallucinations that occur both during sleep ...
Alkermes (ALKS) shifts to fully integrated biopharma, leveraging Vibrance-2, Lybalvi growth, and Avadel buy to de-risk ...
The FDA has granted Breakthrough Therapy designation to alixorexton for the treatment of narcolepsy type 1 (NT1).
TipRanks on MSN
Alkermes gains FDA breakthrough status for narcolepsy drug
The latest announcement is out from Alkermes ( (ALKS) ).
Alkermes wins FDA Breakthrough Therapy status for alixorexton in NT1 after Vibrance-1 data shows improvement in wakefulness.
Potential blockbusters and root-cause treatments from Eli Lilly, Merck, Takeda and others could get a regulatory nod this ...
Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to alixorexton for the treatment of narcolepsy type 1 (NT1), ...
Harmony Biosciences Holdings, Inc. today announced strong preliminary, unaudited net product revenue for Q4 and full year ...
St. Luke’s University Health Network opens a $1.8M expanded Sleep Lab at its Miners Campus, boosting access to sleep disorder ...
Millions of Americans suffer from sleep disorders that can lead to serious health issues, including heart disease, diabetes ...
Jazz Pharmaceuticals plc looks very undervalued at 2.4x sales as oncology catalysts (Ziihera, Zepzelca, Epidiolex) drive ...
Lucid Group, Inc. , maker of the world's most advanced electric vehicles, today announced that the Lucid Gravity SUV has been recognized by the MotorTrend Best Tech Awards for delivering the Best ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback